|
Post by peppy on Mar 27, 2024 10:23:38 GMT -5
UTHR 6 month chart daily Looks like a cup and handle since Dec 14. 6 months daily? That is like being near sided and blind. schrts.co/bPYVyiZn Now what does it look like?
|
|
|
Post by jkendra on Mar 27, 2024 12:03:04 GMT -5
www.weil.com/articles/weil-secures-three-decisive-wins-in-two-business-days-for-united-therapeutics-in-rico-actionsWeil Secures Three Decisive Wins in Two Business Days for United Therapeutics in RICO Actions Download Print March 27, 2024 A Weil team led by Complex Commercial Litigation Co-Head Drew Tulumello secured a series of major victories for long-time client United Therapeutics Corporation (UT), earning three dismissals with prejudice in three separate RICO cases brought against the company in the span of just two business days. The suits faced by UT are part of a trend in which numerous pharmaceutical manufacturers have been hit with RICO lawsuits brought by health insurers on a theory that the manufacturers failed to comply with federal law in connection with alleged donations to charities that provided copayment assistance to patients with certain conditions. As a result, these suits allege that health insurers are forced to cover claims by patients that were not reimburseable and inflated the price of medications. On Friday, March 22, Weil won a dismissal from Chief Magistrate Judge Edwin G. Torres in the United States District Court for the Southern District of Florida in a RICO/antitrust class action brought by MSP Recovery Claims, LLC. MSP had filed RICO and antitrust claims against UT based on assignment agreements it had allegedly received from various health insurers. Judge Torres dismissed these claims for the second time, holding that MSP had failed to plead the requisite proximate cause to support its RICO claims where physicians’ independent decisions to prescribe the medications break the chain of causation and had failed to allege a cognizable RICO injury suffered by the assignors. This case has been pending since July of 2020, and was originally filed in Massachusetts, but Drew’s team persuaded the original court to transfer the case to Florida, which has favorable law on these issues. The very next business day, on Monday, March 26, the Weil team secured two additional dismissals in RICO cases brought by insurers Humana and United Healthcare, two giants in the managed care space. Weil’s briefing persuaded Judge Deborah L. Boardman in the U.S. District Court for the District of Maryland to dismiss both cases with prejudice based in part on an argument that the Weil team had helped pioneer in these copayment assistance cases. Pointing to the indirect purchaser rule established in antitrust law, Drew and team argued that the same rule applied to RICO actions because RICO’s civil-action provision is modeled on those of the federal antitrust statutes. Because Humana and UHC were not direct purchasers of therapies from UT, they lacked statutory standing to bring RICO claims. Judge Boardman agreed, observing that the Fourth Circuit had signaled that the indirect purchaser rule is incorporated into RICO and that other circuits and district courts had reached the same conclusion. Like Judge Torres a day earlier, Judge Boardman also held that Humana and United Healthcare had failed to plead proximate cause, which was an independent basis of dismissal. Judge Boardman’s strong endorsement of these principles may protect life science and biotech companies from future suits by big third-party payors. The Weil team was led by Complex Commercial Litigation Co-Head Drew Tulumello and Complex Commercial Litigation partner Luna Barrington, and included counsel Aaron Curtis and associates Jason Kleinwaks, Sydney Hargrove, Krystel Delauney, Camilla Brandfield-Harvey and Sebastian Laguna.
|
|
|
Post by hellodolly on Apr 16, 2024 8:18:38 GMT -5
SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)-- United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced that recent research across its commercial and development portfolio will be presented at the American Thoracic Society (ATS) International Conference in San Diego on May 17-22, 2024. At ATS, United Therapeutics will host an educational industry theater on implementing treprostinil induction strategies in pulmonary hypertension, and the company is sponsoring the ATS 2024 Women’s Forum.
“We look forward to presenting the latest data on several of our key products and development programs,” said Andrew Nelsen, PharmD,Vice President, Global Medical Affairs at United Therapeutics. “Notably, our academic and industry collaborators will present initial interim efficacy data from the ADVANCE EXTENSION open label extension evaluating extended-release ralinepag for pulmonary arterial hypertension and baseline data updates for the ongoing TETON studies in idiopathic pulmonary fibrosis. We are also pleased to unveil the exciting preliminary findings from our collaboration with Tempus, a leader in artificial intelligence and precision medicine, laying the foundation for earlier identification of patients with pulmonary hypertension.”
I find the last sentence of the last paragraph to be intriguing. They are going to unveil preliminary findings on the research with Tempus, for early detection of patients with PAH. Could be good news for T-DPI over the long run as more scripts may get filled once early patient ID is dialed into the care by treating physicians.
|
|
|
Post by Clement on Apr 16, 2024 9:36:36 GMT -5
SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)-- United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced that recent research across its commercial and development portfolio will be presented at the American Thoracic Society (ATS) International Conference in San Diego on May 17-22, 2024. At ATS, United Therapeutics will host an educational industry theater on implementing treprostinil induction strategies in pulmonary hypertension, and the company is sponsoring the ATS 2024 Women’s Forum. “We look forward to presenting the latest data on several of our key products and development programs,” said Andrew Nelsen, PharmD,Vice President, Global Medical Affairs at United Therapeutics. “Notably, our academic and industry collaborators will present initial interim efficacy data from the ADVANCE EXTENSION open label extension evaluating extended-release ralinepag for pulmonary arterial hypertension and baseline data updates for the ongoing TETON studies in idiopathic pulmonary fibrosis. We are also pleased to unveil the exciting preliminary findings from our collaboration with Tempus, a leader in artificial intelligence and precision medicine, laying the foundation for earlier identification of patients with pulmonary hypertension.”I find the last sentence of the last paragraph to be intriguing. They are going to unveil preliminary findings on the research with Tempus, for early detection of patients with PAH. Could be good news for T-DPI over the long run as more scripts may get filled once early patient ID is dialed into the care by treating physicians. And here's more at ATS from the same PR. It sounds like this collaboration with Tempus might enlarge the patient base. Poster discussion session, Wednesday, May 22, 11:00 a.m. to 1:00 p.m. PT: D102/502 – Structured EHR Data Underestimates Prevalence and Misses Large Proportions of Patients with Pulmonary Hypertension. Presented by RuiJun Chen, M.D., Tempus. Poster discussion session, Wednesday, May 22, 11:00 a.m. to 1:00 p.m. PT: D102/503 – A Novel Phenotyping Pipeline to Improve Identification of Patients with Pulmonary Hypertension in Electronic Health Records. Presented by David Vidmar, Ph.D., Tempus. Poster discussion session, Wednesday, May 22, 11:00 a.m. to 1:00 p.m. PT: D102/504 – ECG-based Machine Learning Model Identifies Patients at High Risk for Incident Pulmonary Hypertension. Presented by Greg Lee, Tempus.
|
|
|
Post by Clement on Apr 16, 2024 10:02:54 GMT -5
^ from Copilot:
Yes, “Pulmonary Hypertension” (PH) is a broad term that includes various types of conditions where there is high blood pressure in the pulmonary arteries. Two of these conditions are “Pulmonary Arterial Hypertension” (PAH) and “Pulmonary Hypertension related to Interstitial Lung Disease” (PH-ILD)123.
PAH is a type of PH where the disease process is primarily located in the pulmonary arteries. On the other hand, PH-ILD is a type of PH where the primary disease process is Interstitial Lung Disease (ILD), and the PH is a complication of that ILD12.
Patients with PH-ILD have symptoms that are very similar to symptoms of ILD without PH, including shortness of breath, lightheadedness, fatigue, and chest discomfort24. It’s important to note that the ways in which ILD or PF can lead to the development of PH are not completely understood2.
So, in summary, both PAH and PH-ILD are included under the umbrella term “Pulmonary Hypertension”, but they refer to different disease processes and have different implications for treatment and prognosis. It’s always best to consult with a healthcare provider for personalized medical advice.
1 meridian.allenpress.com 2 pulmonaryfibrosis.org 3 ucsfhealth.org 4 pulmonaryfibrosis.org
|
|
|
Post by Clement on Apr 19, 2024 6:36:59 GMT -5
|
|
|
Post by Clement on Apr 24, 2024 6:45:21 GMT -5
United Therapeutics Corporation (Nasdaq: UTHR), announced today that it will report its first quarter 2024 financial results before the market opens on Wednesday, May 1, 2024. A press release detailing the quarterly results will be issued that day at approximately 6:30 a.m. Eastern Time. United Therapeutics will host a public webcast Wednesday, May 1, 2024, at 9:00 a.m. Eastern Time. The webcast will be accessible via United Therapeutics' website at ir.unither.com/events-and-presentations. A rebroadcast of the webcast will be available for one year and can be accessed at the same location. finance.yahoo.com/news/united-therapeutics-corporation-report-first-110000608.html
|
|
|
Post by Clement on Apr 24, 2024 11:39:20 GMT -5
|
|
|
Post by uvula on Apr 24, 2024 15:07:34 GMT -5
Fascinating. I can understand accepting a pig organ if no human organs are available. Does anyone know how a clinical trial would work? How would it be different from what they are doing now?
|
|
|
Post by prcgorman2 on Apr 24, 2024 23:18:17 GMT -5
Its been some time since I read what UTHR has in mind, but I thought it was something along the lines of generating replacement organs based on stimulating stem cells harvested from a person needing a replacement organ. They used the term “scaffolding” in relation to what a pig’s anatomy provided. Its kind of mind-blowing. Next-level GMO.
|
|
|
Post by Clement on Apr 30, 2024 7:42:10 GMT -5
UTHR EC is tomorrow morning at 9:00 am.
I'm guessing that T-DPI revs will increase by $40M. This comes mostly from new Tyvaso patients who start on T-DPI but also from conversions due to changes in Medicare reimbursement. Those conversions could include: 1) conversion from PAP (Patient Assistance program) to Medicare and 2) conversion from T-neb Medicare to T-DPI Medicare.
A $40M increase would give UTHR quarterly T-DPI revenue of $253M, which is > $1B annually for T-DPI.
|
|
|
Post by jkendra on Apr 30, 2024 12:10:12 GMT -5
usaherald.com/sandozs-allegations-of-market-poisoning-in-hypertension-medication-trial/apple.news/ASm48IiLIR2yFniPZYGs9QgSandoz’s Allegations of Market Poisoning in Hypertension Medication Trial
In a striking courtroom drama unfolding in New Jersey federal court, Sandoz Inc. has accused biopharmaceutical giant United Therapeutics Corp. of adding “poison” to the market, effectively thwarting the sales of Sandoz’s generic hypertension drug. The two companies are entrenched in a legal battle, with more than $160 million in damages at stake, according to statements made during the opening of a bench trial on Monday. Sandoz Says Biopharma Biz Added ‘Poison’ To Market: The Core of the Conflict The trial, overseen by U.S. District Judge Brian R. Martinotti, aims to ascertain the financial damages incurred by Sandoz after United Therapeutics was found to have violated several laws, including the Sherman Antitrust Act. The conflict centers around the generic drug treprostinil, used to treat pulmonary arterial hypertension, which Sandoz introduced to the market. However, United Therapeutics, the manufacturer of the branded counterpart Remodulin, has been accused of blocking access to necessary delivery devices, compelling patients to rely on a less effective intravenous method. “Your Honor, we are here to talk about damages,” stated Matthew D. Kent, attorney for Sandoz, during the opening statements. He vividly described the situation as “poison” infiltrating the market, influencing both patient access and physician prescription habits. Sandoz Says Biopharma Biz Added ‘Poison’ To Market: Market Poison and its Aftermath Kent argued that this market poisoning continued to deter doctors from prescribing the generic option, with the adverse effects still permeating the industry. According to Kent, the damages owed to Sandoz tally up to a substantial $168.4 million. In contrast, Edward J. Bennett, representing United Therapeutics, attributed the poor uptake of Sandoz’s generic to ineffective marketing and administrative errors. He downplayed the alleged damages, suggesting a mere $8 million would be sufficient. Sandoz Says Biopharma Biz Added ‘Poison’ To Market: A History of Legal Struggles This legal confrontation is not the first between Sandoz and United Therapeutics. They previously clashed in 2015 over patent issues, which was resolved when Sandoz obtained a nonexclusive license to sell its generic version. However, the contention reignited as United Therapeutics allegedly employed new strategies to suppress the generic drug’s market presence, including restricting the distribution of essential drug delivery pumps through specialty pharmacies unless paired with their branded drug. As the trial progresses, the legal teams—Sandoz represented by Alston & Bird LLP and Quinn Emanuel Urquhart & Sullivan LLP, and United Therapeutics by Williams & Connolly LLP and Blank Rome LLP—will continue to unveil the complexities of this significant case, which could have far-reaching implications for the pharmaceutical industry. The case, officially titled Sandoz Inc. et al. v. United Therapeutics Corp. et al., is documented under case number 2:19-cv-10170 in the U.S. District Court for the District of New Jersey.
|
|
|
Post by prcgorman2 on Apr 30, 2024 14:10:02 GMT -5
Trial begins two days before UTHR's 1st quarter earnings. You can't make this stuff up.
|
|
|
Post by kite on May 1, 2024 5:43:14 GMT -5
United Therapeutics Corporation Reports First Quarter 2024 Financial Results
SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)-- United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced its financial results for the quarter ended March 31, 2024. Total revenues in the first quarter of 2024 grew 34 percent year-over-year to $677.7 million, compared to $506.9 million in the first quarter of 2023.
Total Tyvaso revenues grew by 56 percent to $372.5 million in the first quarter of 2024, compared to $238.4 million in the first quarter of 2023. This growth was primarily due to an increase in quantities sold, driven by the commercial launch of Tyvaso DPI in June 2022 and continued growth in commercial utilization by patients with pulmonary hypertension associated with interstitial lung disease and, to a lesser extent, a price increase.
The growth in Tyvaso DPI revenues resulted primarily from an increase in quantities sold and, to a lesser extent, a price increase. The increase in Tyvaso DPI quantities sold was due to continued growth in the number of patients following the product's launch and, to a lesser extent, increased commercial utilization following the implementation of the Part D redesign under the Inflation Reduction Act.
The growth in nebulized Tyvaso revenues resulted primarily from inventory destocking by our distributors in the first quarter of 2023, which did not reoccur during the first quarter of 2024.
|
|
|
Post by cppoly on May 1, 2024 6:00:15 GMT -5
Tyvaso DPI is up 92% in Q124 with 227.5 million compared to 118.7 million from Q123
|
|